Project Grant R01NS142141
Award Date 8/1/25
Completion Date 7/31/30
Dollars Obligated $657K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dallas, TX 75390, USA
Similar Awards
- This federal Project Grant award for $659,325.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The grant supports research to understand the role of mutant IDH1 in glioma pathophysiology and immune response mechanisms. The research will use a novel murine glioma model developed by incorporating genetic lesions into neural progenitor cells using the...
- The Project Grant award of $412,499.00 from the Department of Health and Human Services National Institutes of Health (NIH) Trans-NIH Research Support program (CFDA 93.310) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), supports research on the molecular mechanisms of mutant IDH inhibition and DNA damage in IDH-mutant glioma. The project aims to use a newly developed genetically engineered mouse model of IDH-mutant grade 3 astrocytoma to understand...
- This federal Project Grant award of $460,940 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research conducted by the University of Texas MD Anderson Cancer Center to investigate how genetic risk factors for glioma, a type of brain cancer, impact neurodevelopmental processes and potentially promote tumor formation. The research leverages human...
- This federal Project Grant award of $2,467,799 from the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), is supporting research at Washington University to understand the role of the myeloid cell metabolic enzyme wild-type IDH1 (WT-IDH1) in glioblastoma. The research aims to investigate how targeting WT-IDH1 in tumor-associated myeloid cells can reprogram the tumor microenvironment to enhance anti-tumor immune responses and slow glioblastoma growth. This 4-year...
- This $245,434 federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research at the University of Pennsylvania to map the neural circuit connectivity of human high-grade glioma brain tumors in a mouse model. The goal is to define the whole-brain inputs onto glioblastoma cells using monosynaptic tracing techniques to understand how neuronal...
- This federal Project Grant award of $131,360 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, is funding research at the University of New Haven to characterize the long non-coding RNA GIHCG and assess its potential as a therapeutic target for glioblastoma, the most aggressive form of brain cancer. The 4-year project aims to use CRISPR/Cas9 gene editing to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $682,596 to The University of Texas Southwestern Medical Center to conduct research on the metabolic mechanisms driving glioma progression. The key research objectives are to: 1) Dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas; 2) Determine the impact of aberrant metabolite secretion on the tumor microenvironment; and...
- This federal Project Grant award of $610,554.00 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to mechanistically link and leverage the interrelated findings on tumor-induced alterations in peritumoral neuronal mTOR and GABAergic signaling. The research aims to understand how these alterations contribute to both tumor-associated seizures and...
- This federal Project Grant award of $429,000 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, aims to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells. The goal is to develop novel therapies for this deadly brain cancer. The research project, led by the Regents of the University of Michigan, will identify GBM...
- The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $147,486 Project Grant under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) to the Baylor College of Medicine. The grant supports research to define the role of the germline DAAM2 variant R414W in familial glioma, the most common subtype of primary brain tumor in adults. The research aims to investigate how this newly discovered DAAM2 variant contributes to glioma...